NetworkNewsBreaks – Endonovo Therapeutics Inc. (
Post# of 416
(Total Views: 901)
Posted On: 11/20/2019 3:42:32 PM
NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Announces Q3 2019 Results
Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, on Tuesday announced its financial results for the quarter ended September 30, 2019. Among the highlights, Endonovo reported a 153% increase in revenues for the three months ended September 30, 2019 to $54,039 and a 293% increase in revenues for the nine months ended September 30, 2019 to $161,720, as compared to the same periods last year. “Although our third-quarter operating results and our revenues failed to meet previously announced projections, the efforts throughout the quarter and first nine-months of this year have been extremely positive considering the amount of hospitals we are currently in and the number of hospitals evaluating SofPulse(R) to date,” Endonovo Therapeutics CEO Alan Collier said in the news release. “The national rollout has been successful, however, hospitals testing and evaluation periods have been longer than initially expected. We respect the process, the policies and procedures some hospitals have before accepting a product into their medical facility and as part of their post-operative pain management protocols. As such, we continue to expand our client base and have seen significant traction in building Endonovo into a premier supplier to hospitals nationwide for post-operative pain.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, on Tuesday announced its financial results for the quarter ended September 30, 2019. Among the highlights, Endonovo reported a 153% increase in revenues for the three months ended September 30, 2019 to $54,039 and a 293% increase in revenues for the nine months ended September 30, 2019 to $161,720, as compared to the same periods last year. “Although our third-quarter operating results and our revenues failed to meet previously announced projections, the efforts throughout the quarter and first nine-months of this year have been extremely positive considering the amount of hospitals we are currently in and the number of hospitals evaluating SofPulse(R) to date,” Endonovo Therapeutics CEO Alan Collier said in the news release. “The national rollout has been successful, however, hospitals testing and evaluation periods have been longer than initially expected. We respect the process, the policies and procedures some hospitals have before accepting a product into their medical facility and as part of their post-operative pain management protocols. As such, we continue to expand our client base and have seen significant traction in building Endonovo into a premier supplier to hospitals nationwide for post-operative pain.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Endonovo Therapeutics, Inc. (ENDV) Stock Research Links
Scroll down for more posts ▼